Skip to Content

Perspective of first line immune therapy of non-small-cell lung cancer

In this MEDtalk Ahmet Sezer, MD, professor, Department of Medical Oncology, Başkent University, Adana, Turkey, gives his perspective on treatment of non-small cell Lung cancer with immune therapy as first line treatment. He also gives his answer on how oncologists can choose wisely and how he would explain the survival benefit in the cemiplimab arm according to EMPOWER Lung 1 study.

Ahmet Sezer

Avaa artikkeli

Jos olet lääkäri, sairaanhoitaja tai muu terveydenhuollon ammattilainen, voit käyttää koko artikkelia luomalla profiilin BestPractice Nordic -sivustolle.

Back to top